8-K: QuidelOrtho Reports Strong FY25 Growth, Positive FY26 Outlook

QuidelOrtho announced its fourth quarter and full-year 2025 financial results, highlighting growth in core diagnostics and significant margin expansion, alongside a positive outlook for 2026.

Summary

• Total revenue for Q4 2025 was $724 million, and for full-year 2025 was $2.73 billion.
• Non-respiratory revenue, excluding Donor Screening, grew 7% in constant currency for Q4 2025 and 5% for full-year 2025.
• Labs revenue grew 8% as reported and 7% in constant currency for Q4 2025, and 6% for full-year 2025.
• Respiratory revenue declined 14% in Q4 2025 to $123 million and 20% for full-year 2025 to $402 million, primarily due to lower COVID-19 testing.
• Flu revenue grew 6% in Q4 2025 and 3% for full-year 2025.
• GAAP net loss was $131 million for Q4 2025 and $1.13 billion for full-year 2025, which included a non-cash goodwill impairment charge of $701 million in Q3 2025.
• Adjusted EBITDA was $153 million for Q4 2025 and $597 million for full-year 2025, with a full-year adjusted EBITDA margin of 22%, a 240 basis point improvement.
• Adjusted diluted EPS was $0.46 for Q4 2025 and $2.12 for full-year 2025.
• Free cash flow was $87 million for Q4 2025, but negative $(77) million for full-year 2025, including one-time investments in an ERP system conversion completed in Q3 2025.
• The company achieved $140 million in cost-savings by the end of 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively, reflecting a successful transition from COVID-driven revenue, strong underlying business growth in core segments, significant margin expansion, and a robust outlook for free cash flow and profitability in 2026, despite a non-cash goodwill impairment charge impacting GAAP net loss in 2025.

Positives

• Labs revenue demonstrated consistent growth, increasing 8% as reported and 7% in constant currency for Q4 2025, and 6% for full-year 2025.
• Non-respiratory revenue, excluding Donor Screening, showed strong growth of 7% in constant currency for Q4 2025 and 5% for full-year 2025.
• Adjusted EBITDA margin expanded by 240 basis points to 22% for full-year 2025, reflecting effective cost-savings initiatives.
• Flu revenue grew 6% in Q4 2025 and 3% for full-year 2025, indicating strength in seasonal diagnostics.
• The company projects substantially stronger free cash flow for FY2026, expected to improve by over $200 million to $120 $160 million, compared to $(77) million in FY2025.
• FY2026 guidance anticipates continued growth and margin expansion, with adjusted EBITDA projected to be $630 $670 million and adjusted EBITDA margin at 23.3%.

Negatives

• GAAP net loss was significant at $1.13 billion for full-year 2025, primarily due to a non-cash goodwill impairment charge of $701 million recorded in Q3 2025.
• GAAP operating loss for full-year 2025 was $0.92 billion.
• Respiratory revenue declined by 20% for full-year 2025, driven by lower COVID-19 testing demand.
• Free cash flow for full-year 2025 was negative $(77) million, impacted by one-time investments in ERP system conversion.
• The company is in the process of winding down its U.S. Donor Screening portfolio, which saw a 54.3% decline in revenue for full-year 2025.

Risks

• Fluctuations in demand for non-respiratory and respiratory products.
• Supply chain, production, logistics, distribution, and labor disruptions and challenges.
• Failure to acquire or complete the proposed acquisition of LEX Diagnostics on the anticipated timeline, or at all, including risks related to FDA clearance and satisfying closing conditions.
• Inability to successfully identify, consummate, or realize the anticipated benefits of strategic transactions, restructurings, divestitures, spin-offs, discontinuances of certain business operations, or debt financings.
• Delays in the development of or failures or delays in the receipt of approvals for new or enhanced products.
• Failure of new products and services to be commercially viable or accepted.
• Macroeconomic, geopolitical, market, business, competitive, and/or regulatory factors, including those arising from tariffs, trade policies, investigations, and global trade relations.

Future Outlook

QuidelOrtho anticipates continued growth and margin expansion in fiscal year 2026, with projected total revenues between $2.7 billion and $2.9 billion, adjusted EBITDA of $630 million to $670 million, and an adjusted EBITDA margin of 23.3%. The company expects a substantial improvement in free cash flow, forecasting $120 million to $160 million, and adjusted diluted EPS between $2.00 and $2.42. Foreign currency exchange is expected to be neutral to full-year 2026 revenue.

Management Comments

• Brian J. Blaser, President and CEO, stated: "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business. Our Labs, Immunohematology and Cardiac businesses delivered consistent growth, while cost-savings initiatives drove meaningful margin expansion. As a result, we are well positioned to generate substantially stronger free cash flow in 2026, which we believe more accurately reflects the earnings power of our business."
• Brian J. Blaser commented on the CFO's retirement: "Joe has been instrumental in strengthening our financial discipline and delivering $140 million in cost-savings by the end of 2025. With our financial strategy firmly in place and a strong team supporting the transition, we are confident in our ability to execute our 2026 priorities and maintain momentum."

Industry Context

StockSavvy.ai notes that QuidelOrtho's transition from COVID-driven revenue volatility to a more diversified diagnostics business aligns with broader industry trends as the pandemic's immediate impact wanes. The focus on core diagnostics segments like Labs, Immunohematology, and Cardiac, coupled with significant margin expansion through cost-savings, positions the company to capitalize on stable demand in the in vitro diagnostics market. The projected improvement in free cash flow for 2026 suggests a strengthening financial profile in a competitive landscape.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from meeting FY2025 guidance, strong adjusted EBITDA margin expansion, and positive FY2026 outlook for revenue, EBITDA, and free cash flow, potentially offset by the significant GAAP net loss due to goodwill impairment.
• Employees: Transition in the Chief Financial Officer role, with a search underway for a successor and an advisory role for the outgoing CFO to ensure a smooth transition.
• Customers: Continued focus on core diagnostics businesses (Labs, Immunohematology, Cardiac) and innovation to advance diagnostics, aiming to improve patient outcomes.

Next Steps

• QuidelOrtho will hold an earnings conference call on February 11, 2026, at 2:00 p.m. Pacific Time to discuss the financial results.
• The company has initiated a search to identify a successor for the retiring Chief Financial Officer, Joseph M. Busky.
• Joseph M. Busky will serve in an advisory role following his retirement to facilitate a smooth transition.
• The company aims to execute its 2026 priorities and maintain momentum, focusing on continued growth and margin expansion.

Key Dates

Recommendation

QuidelOrtho's strong performance in core non-respiratory diagnostics, significant adjusted EBITDA margin expansion, and successful cost-savings initiatives demonstrate a robust underlying business. The positive FY2026 guidance, particularly the projected substantial improvement in free cash flow, indicates a healthy financial trajectory. While the GAAP net loss for FY2025 is notable, it is largely attributable to a non-cash goodwill impairment charge, which does not reflect the operational strength. For a seasoned investor, the company's strategic transition to a more durable, diversified business and its clear path to enhanced profitability and cash generation make it an attractive investment.

Keywords

Diagnostics, In Vitro Diagnostics, Financial Results, QDEL, Earnings, Medical Devices, Laboratory Diagnostics, Point-of-Care, Immunoassay, Molecular Testing, Adjusted EBITDA, Free Cash Flow, Goodwill Impairment